Angeles Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Angeles Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-375	Closed	-$238K	–	447
2025 Q1	$238K	Buy	375 +16	+4%	+$11K	0.02%	257
2024 Q4	$256K	Sell	359 -2	-0.6%	-$1.68K	0.02%	246
2024 Q3	$379K	Buy	361 +10	+3%	+$11.1K	0.03%	164
2024 Q2	$369K	Buy	351 +26	+8%	+$25.2K	0.03%	151
2024 Q1	$313K	Buy	325 +11	+4%	+$10.5K	0.03%	165
2023 Q4	$276K	Buy	314 +2	+0.6%	+$1.65K	0.03%	155
2023 Q3	$257K	Buy	312 +26	+9%	+$20.4K	0.04%	145
2023 Q2	$206K	Sell	286 -1	-0.3%	-$771	0.03%	175
2023 Q1	$236K	Buy	+287	New	+$216K	0.04%	158

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Angeles Wealth Management's REGN Position: Q2 2025 in Review

Angeles Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 375 shares — an estimated $238K sold.

Angeles Wealth Management first reported a position in REGN in Q1 2023 and held it in 9 quarters. The position peaked at $379K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Angeles Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Angeles Wealth Management sold 375 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $238K.
Angeles Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 9 quarters.
Angeles Wealth Management's Regeneron Pharmaceuticals position peaked at $379K in Q3 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Angeles Wealth Management's 13F filing for Q2 2025, filed 29 Jul 2025.